Replimune Announces Pricing of $150 Million Underwritten Offering

Replimune (Nasdaq: REPL) priced an underwritten offering of 9,701,490 common shares at $12.06 per share and pre-funded warrants to purchase 2,736,340 shares at $12.0599 per warrant.

Rhea-AI Summary

Replimune (Nasdaq: REPL) priced an underwritten offering of 9,701,490 common shares at $12.06 per share and pre-funded warrants to purchase 2,736,340 shares at $12.0599 per warrant. Expected aggregate gross proceeds are about $150 million, before underwriting discounts, commissions, and expenses.

All securities will be sold by Replimune, with closing expected on August 11, 2026, subject to customary conditions. Leerink Partners, J.P. Morgan, and Cantor are acting as joint bookrunning managers under an effective shelf registration on Form S-3.

Positive

• $150 million expected gross proceeds before fees and expenses
• Underwritten sale of 9,701,490 shares at $12.06 each
• Pre-funded warrants for 2,736,340 shares priced at $12.0599
• Offering led by three bookrunning managers: Leerink Partners, J.P. Morgan, Cantor

Negative

• Issuance of 9,701,490 new shares plus 2,736,340 warrant shares will dilute existing shareholders
• Net proceeds will be below the stated $150 million gross due to underwriting discounts and offering expenses

News Explained

The priced offering could reduce existing ownership percentages and equals 240.4 days of the latest quarter’s operating cash use before transaction costs.

The offering is priced but has not closed; Replimune is the seller, and issuing the shares and any shares from exercised warrants would reduce existing holders’ percentage ownership.

A pre-funded warrant is sold at nearly the common-share price with a nominal exercise price and converts into shares when exercised, making these warrants an additional share-issuance mechanism.

For scale, the $150 million gross offering equals 240.4 days of the last reported quarter’s operating cash use. Cash and equivalents as of March 31, 2026 were $209,024,000, alongside $59,865,000 of short-term investments.

Sources and calculations

• Replimune Announces Pricing of $150 Million Underwritten Offering (2026-08-10)
• Dilution (2026-07-17)
• Pre-funded warrant (2026-07-17)
• Replimune latest-quarter fundamentals (2026Q4)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $150,000,000 / ($56,161,000 / 90) = 240.4 days

Argus Aug 10 session 38 alerts

+13.35% close to close 0.8x rel. volume Open Argus

Details

Market move: REPL +13.35% in the Aug 10 session. underwritten public offering

+22.4% Peak Tracked

-4.7% Trough Tracked

$1.19B Market Cap

On Aug 10, the day this news came out, REPL closed 13.35% above the previous close. Argus tracked a peak move of +22.4% during that session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner recorded 38 alerts for this stock that day.

Data tracked by StockTitan Argus for the Aug 10 session.

Key Figures

Common shares offered: 9,701,490 shares Common share offering price: $12.06 per share Pre-funded warrant shares: 2,736,340 shares +4 more

Common shares offered

9,701,490 shares

Underwritten offering

Common share offering price

$12.06 per share

Underwritten offering

Pre-funded warrant shares

2,736,340 shares

In lieu of common stock for certain investors

Pre-funded warrant purchase price

$12.0599 per warrant

Underwritten offering

Warrant exercise price

$0.0001 per share

Pre-funded warrants

Gross proceeds

Approximately $150 million

Before underwriting discounts, commissions, and expenses

Expected closing date

August 11, 2026

Subject to customary closing conditions

Previous Offering Reports

2 past events · Latest: Nov 25

Same Type 2 events

1. Nov 25

   public offering

   24h Move

   +8.4%

   Upsized public offering of common shares and pre-funded warrants

2. Nov 25

   public offering

   24h Move

   -11.2%

   Proposed public offering of common stock and pre-funded warrants

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten offering, pre-funded warrants, shelf registration statement, form s-3

4 terms

underwritten offering financial

"announced the pricing of an underwritten offering"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

pre-funded warrants financial

"pre-funded warrants to purchase 2,736,340 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"pursuant to its shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an offering price of $12.06 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares of its common stock at a purchase price of $12.0599 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by Replimune. The offering is expected to close on August 11, 2026, subject to the satisfaction of customary closing conditions.

Leerink Partners, J.P. Morgan, and Cantor are acting as the bookrunning managers for the offering.

The securities are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Replimune with the Securities and Exchange Commission (the “SEC”) on May 23, 2025, as amended by Amendment No. 1 to the Registration Statement on Form S-3 filed with the SEC on November 6, 2025. A prospectus supplement relating to the offering, and the accompanying prospectus, will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; and Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies, including the Company’s first commercially available product TUDRIQEVTM (vusolimogene oderparepvec-wtpg), approved under accelerated approval by the U.S. Food and Drug Administration in combination with nivolumab for the treatment of adults with advanced melanoma who experienced disease progression on a PD-1 antibody-based regimen. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response. Upon intratumor injection, RPx causes direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens, alteration of the tumor microenvironment, and when dosed in combination with an immune checkpoint inhibitor immunotherapy, it may ignite a systemic anti-tumor response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options.

Forward-Looking Statements

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the timing of closing of our offering, the gross proceeds we expect to receive from our offering and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited experience in commercializing products for sale, our ability to successfully verify the clinical benefit of TUDRIQEV in our ongoing confirmatory Phase 3 trial, IGNYTE-3, our ability to meet our product manufacturing goal, the timing and scope of future regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, the impact of political and global macro factors and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of Replimune (NASDAQ: REPL) $150 million underwritten offering announced on August 10, 2026?

Replimune priced an underwritten offering expected to raise about $150 million in gross proceeds. According to Replimune, it is selling 9,701,490 common shares at $12.06 and pre-funded warrants for 2,736,340 shares at $12.0599 under an effective shelf registration.

How many shares and pre-funded warrants is Replimune (REPL) offering in its 2026 underwritten deal?

Replimune is offering 9,701,490 common shares and pre-funded warrants to purchase 2,736,340 additional shares. According to Replimune, the shares are priced at $12.06 each and the pre-funded warrants at $12.0599, with a $0.0001 per share exercise price.

What is the expected closing date of Replimune’s August 2026 underwritten offering of REPL stock?

The offering is expected to close on August 11, 2026, subject to customary closing conditions. According to Replimune, all securities in the transaction will be sold by the company under its previously filed Form S-3 shelf registration statement.

How much money will Replimune (REPL) receive from its August 2026 equity and warrant offering?

Replimune expects aggregate gross proceeds of approximately $150 million from the offering. According to Replimune, this amount is before deducting underwriting discounts, commissions, and other offering expenses, so the final net proceeds to the company will be lower than $150 million.

Who are the bookrunning managers for Replimune’s (NASDAQ: REPL) August 2026 underwritten offering?

The bookrunning managers are Leerink Partners, J.P. Morgan, and Cantor. According to Replimune, these firms are acting as joint bookrunning managers for the common stock and pre-funded warrant offering conducted under the company’s effective Form S-3 shelf registration statement.

How might Replimune’s 2026 $150 million stock and warrant sale affect existing REPL shareholders?

The transaction will increase Replimune’s share count through 9,701,490 new shares and 2,736,340 warrant shares, diluting existing holders. According to Replimune, all securities are being sold by the company, so ownership percentages of current shareholders will decline.

Where can investors find the prospectus for Replimune’s August 2026 REPL underwritten offering?

Investors can access the prospectus supplement and accompanying prospectus via the SEC’s EDGAR website once filed. According to Replimune, copies may also be requested from Leerink Partners, J.P. Morgan, or Cantor through their listed postal and email contacts.